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Abstract
The utilisation of the Na/I symporter (NIS) and associated radiotracers as a reporter system for imaging gene expression is
now reaching the clinical setting in cancer gene therapy applications. However, a formal assessment of the methodology
in terms of normalisation of the data still remains to be performed, particularly in the context of the assessment of
activities in individual subjects in longitudinal studies. In this context, we administered to mice a recombinant, replication-
incompetent adenovirus encoding rat NIS, or a human colorectal carcinoma cell line (HT29) encoding mouse NIS. We used
99mTc pertechnetate as a radiotracer for SPECT/CT imaging to determine the pattern of ectopic NIS expression in
longitudinal kinetic studies. Some animals of the cohort were culled and NIS expression was measured by quantitative RT-
PCR and immunohistochemistry. The radioactive content of some liver biopsies was also measured ex vivo. Our results
show that in longitudinal studies involving datasets taken from individual mice, the presentation of non-normalised data
(activity expressed as %ID/g or %ID/cc) leads to ‘noisy’, and sometimes incoherent, results. This variability is due to the
fact that the blood pertechnetate concentration can vary up to three-fold from day to day. Normalisation of these data
with blood activities corrects for these inconsistencies. We advocate that, blood pertechnetate activity should be
determined and used to normalise the activity measured in the organ/region of interest that expresses NIS ectopically.
Considering that NIS imaging has already reached the clinical setting in the context of cancer gene therapy, this
normalisation may be essential in order to obtain accurate and predictive information in future longitudinal clinical
studies in biotherapy.
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Introduction
The sodium iodide symporter (NIS) is an integral membrane
glycoprotein that mediates the uptake and concentration of iodide
into cells. This protein is mainly expressed in the thyroid and
stomach [1], although expression has been detected at other
anatomical locations [2,3]. In gene and cell therapies, ectopic NIS
expression, associated with relevant radioisotopes such as
123I
2,
124I
2 or
99mTcO4
2, has been used extensively in rodent models to
monitor the efficacy of gene transfer using various imaging
modalities (PET and SPECT) [1,4]. With this technology, it is
possible to evaluate the patterns of gene expression allowed by
different gene delivery vectors [5,6,7,8,9,10,11,12] or to assess the
specificities of particular promoters [13,14,15,16]. More recently,
this methodology has been used to monitor the fates of cells with
therapeutic potential which have been genetically-modified to
express NIS [17,18,19,20,21]. In addition, it is possible to combine
the imaging and therapeutic potentials of NIS to optimise
radionuclide administration in cancer gene therapy [22,23]. The
status of NIS as a relevant reporter gene for SPECT imaging in
cancer gene therapy has been validated recently in phase 1 clinical
trials using conditionally replicating adenovirus [24,25], although
vector design and dose are critical to the successful visualisation of
transgene expression [26].
The question of whether NIS imaging can provide quantitative
information regarding transgene expression levels has been
addressed in different experimental models: PET imaging of liver
transduction using a
124I
2 radiotracer [27], SPECT imaging of
tumour transduction using
123I
2 or
99mTcO4
2 radiotracers
[28,29,30] and SPECT imaging of cardiac gene therapy using a
123I
2 radiotracer [21] were used to validate the methodology.
Altogether, these studies demonstrated a good correlation between
radiotracer accumulation and NIS gene and protein expression
levels, as well as between radiotracer uptake measured by imaging
and direct counting of the radioactivity associated with biopsies.
There is, however, no consensus on how to present the data. Some
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e34086authors have expressed their results as %ID/g (percentage of
injected dose per gram of tissue) [21,27,28], while others have
presented their data as a ratio of radiotracer accumulation in the
transduced organ versus that in non-transduced tissues, taken as
background [29]. The latter has the advantage of accounting for
background values and is therefore less likely to be susceptible to
individual experimental artefacts or variations. This point is
particularly important as, unlike other reporter gene systems
developed for PET or SPECT imaging, the amount of radiotracer
localised in NIS-expressing tissues varies depending on its blood
concentration. In addition, when
131I
2 is used to treat differen-
tiated thyroid carcinomas in humans, it is known that uptake to
the target tissue, and thus treatment success, is more dependent on
the blood concentration than on administered activity [31,32].
There is, thus, a theoretical risk of artefactual variability.
Considering that the monitoring of gene expression and transfer
using NIS has been validated in patients [24,25], and that the
images obtained are used to evaluate the feasibility of
131I
radioiodine therapy through dosimetric determinations [25], a full
assessment of the methodology is required, particularly in the
context of the assessment of activities in individual subjects in
longitudinal studies, where data cannot be smoothed by a
statistical analysis.
In the present work, we examined this issue using SPECT/CT
and
99mTcO4
2 as radiotracer in kinetics spanning more than sixty
days after NIS gene transfer. More specifically, we determined
whether quantitative data presented as %ID/g or %ID/cc provide
a correct assessment of ectopic NIS transgene expression or
whether blood-normalised-uptake (BNU) corrections are necessary
to obtain a coherent dataset.
Results
SPECT/CT imaging and immunohistochemistry of NIS
expression upon systemic injection of Ad-CMV-rNIS
To visualise gene transfer, Ad-CMV-rNIS doses varying from
5610
8 to 1610
9 PFU were injected systemically to Balb/c mice.
Serial SPECT/CT scans were performed, upon injection of the
99mTcO4
2 radiotracer up to 60 d after virus administration. Fig. 1
shows representative, selected coronal, transverse and sagittal
views obtained 2 d after the administration of saline buffer
(Fig. 1A) or 5610
8 (Fig. 1B) or 1610
9 PFU (Fig. 1C) Ad-CMV-
rNIS. As expected from previous studies [33,34], significant
activity was noted in the liver when the animals were injected with
1610
9 PFU virus, as a result of ectopic NIS expression in this
organ. Transgene expression was very significantly lower when
5610
8 PFU were administered (Figs. 1B versus 1C). In both cases,
the activity was detectable from 5 h post virus administration (not
shown). In addition, radiotracer accumulation was observed in the
spleen 24 h after virus administration but this uptake was only
transient and disappeared rapidly (not shown). Immunohistolog-
ical staining of liver biopsies of these animals confirmed the
dramatic difference observed by SPECT/CT in NIS expression
(Fig. 2). In the animals administered with 1610
9 PFU Ad-CMV-
rNIS, more than 90% of hepatocytes showed NIS-specific
immunoreactivity (Figs. 2C and 2F).
Measurement of blood and muscles activity
To determine the blood activity, and at each time-point, a 2-
mm-diameter region of interest in the left ventricular cavity of the
heart was drawn, using fused SPECT/CT images. Fig. 3 shows
Figure 1. Imaging of NIS expression by microSPECT-CT. Transverse, coronal and sagittal slices from SPECT images of Balb/c mice intravenously
injected with (A) saline buffer (n=4), (B) 5610
8 PFU (n=3) or (C) 1610
9 PFU Ad-CMV-rNIS (n=3). Forty-eight hours later, mice received an
intraperitoneal injection of 100 MBq
99mTcO4- and were imaged with a microSPECT-CT camera (eXplore speCZT, General Electric). (S) stomach and (L)
liver.
doi:10.1371/journal.pone.0034086.g001
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animal to another. Despite the fact that a strictly identical protocol
was used for the whole study, the blood pertechnetate content
varied between 2 %ID/cc and more than 6%ID/cc. Importantly,
the comparison between blood content in adenovirus-injected
(5610
8 and 1610
9 PFU) animals and non-injected controls did
not change significantly, indicating that strong expression of NIS
in the liver did not significantly affect the pertechnetate content of
the blood (Fig. 3A). Regions of interests of similar sizes were drawn
in the neck muscles and quadriceps of experimental animals and
the activities were compared to blood activities. Fig. 3B shows a
good correlation between neck muscle and blood activity
(R
2=0.90), while a poor correlation was observed between
quadriceps and blood activity (R
2=0.030, Fig. 3C).
Correlation between 99mTcO42 uptake measured by
SPECT/CT and by post-mortem b-counting of a biopsy
To establish whether the quantitative data obtained from
SPECT/CT images are accurate, 6 animals were culled 3 days
after virus injection, liver biopsies were collected, their radioactive
content measured immediately after cull and compared with those
calculated from SPECT/CT imaging. Fig. 4A shows a good
correlation (R
2=0.73) between activities measured by SPECT/
CT imaging (expressed in %ID/cc) and post-mortem b-counting
of biopsies. When the same comparison was performed using
blood-normalised uptakes (BNU) (Fig. 4B), the correlation was
even greater (R
2=0.89). In separate animals administered with
either 5610
8 (n=3) or 1610
9 PFU (n=3) Ad-CMV-rNIS, liver
biopsies were collected to compare NIS gene expression and
radiotracer accumulation measured by SPECT (Fig. 5). Quanti-
tative RT-PCR analysis measuring NIS transcript levels showed
that liver NIS expression increased with adenovirus dose
administered (Fig. 5A) and that a good correlation (R
2=0.83)
could be established between the relative NIS expression levels
and radiotracer uptake in the liver normalised to that of the blood,
measured by SPECT/CT (Fig. 5B). When non-normalised data
are analysed, an even greater coefficient of correlation is obtained
(R
2=0.93). Altogether, these results demonstrate that SPECT can
provide quantitative information on the level of ectopic NIS
expression in the liver. When the dataset is analysed using
statistics, the normalisation to blood activity provides accurate
data but this normalisation is not an absolute requirement.
Long-term kinetic study after adenoviral vector-mediated
gene transfer to the liver
Mice administered with either 5610
8 or 1610
9 PFU Ad-CMV-
rNIS were scanned serially. For each experimental point, ROIs of
4 mm diameter were drawn in ‘representative’ areas of the right
and left lobes of the liver and the average values were used to
calculate the %ID/cc at each time-point. The kinetics presented in
Figs. 6A and 6B show that, upon administration of 5610
8 PFU
Ad-CMV-rNIS, radiotracer uptake reaches its maximal level
between 48 h and 3 d after virus injection and decreases
afterwards to reach a near-basal level by day 21. By contrast,
upon injection of 1610
9 PFU virus, a near-maximum radiotracer
uptake is still observed in the liver 21 d after virus administration
(Figs. 6C and 6D) and the near-basal level is only reached after
60 d (Fig. 6D). Overall, these kinetics are in good agreement with
Figure 2. Immunohistochemical staining of NIS protein in adenovirus-transduced livers. Representative NIS immunostaining of liver
sections from control (panels A and D) and Ad-CMV-rNIS-injected mice (panels B and E: 5610
8 PFU, panels C and F: 1610
9 PFU). Livers taken from
one animal per condition were processed. Magnification: see bars on panels. Si: sinusoidal capillaries, H: hepatocytes.
doi:10.1371/journal.pone.0034086.g002
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experimental animals but the kinetics in individual animals
showed rather incoherent results, at specific time-points (Figs. 6B,
6C, 6D). Activities in the liver increased, decreased and increased
again in a manner not compatible with reported studies of liver
transduction with a replication-deficient adenovirus [33], suggest-
ing an experimental or methodological bias. These inconsistencies
were not linked with the choice of ROI, as different ROIs
positioned differently in the liver produced a similar dataset (not
shown).
A possible explanation for the apparently incoherent liver
uptake of
99mTcO4
2 in Ad-CMV-rNIS-transduced mice (Figs. 6B,
6C, 6D) could be the variability in the
99mTcO4
2 blood content
demonstrated in Fig. 3. To address this question, and at each time-
point, the liver activity was normalised to that of the blood. The
results presented in Figs. 6E, 6F, 6G and 6H show a much more
coherent dataset than without the blood correction.
Imaging of NIS-expressing cells
HT29-NIS cells were injected in the liver of SCID mice and
pertechnetate uptake was determined by SPECT/CT imaging.
Fig. 7A shows the volume rendering of the pertechnetate uptake
by hepatic tumours, at different times after HT29-NIS adminis-
tration. The quantitative analyses were performed by drawing
Figure 3. Comparison of blood SPECT activity in control and
Ad-CMV-rNIS-injected mice. A. Balb/c mice were injected intrave-
nously with saline buffer (empty circles), 5610
8 PFU (black circles) or
1610
9 PFU (squares) Ad-CMV-rNIS. Four days later, SPECT/CT imaging
was performed. ROIs were drawn in the left ventricular cavity of the
heart. The activity was calculated and converted to %ID/cc. B and C.
Mice were scanned by SPECT/CT and the blood activity (measured as
described above) was compared with the activity in the neck muscles
(B) or in the quadriceps (C). For calculations of the activities in the
muscles, a ROI of similar size to that used for the calculation of the
blood activity was drawn and positioned on the muscles.
doi:10.1371/journal.pone.0034086.g003
Figure 4. Comparison of the
99mTcO4
2 uptake determined by
ex-vivo b–counting of liver biopsies and measured by SPECT/
CT. Balb/c mice were injected intravenously with either 5610
8 (circles)
or 10
9 PFU (squares) Ad-CMV-rNIS. Four days later, 100 MBq
99mTcO4
2
were injected intraperitoneally and SPECT imaging was performed.
Blood and liver activities were measured. After imaging, the radioac-
tivity in the liver of each individual mouse was measured ex vivo. Values
were expressed as (A) a percentage of the injected dose per volume
(%ID/cc) or (B) normalised to blood activity.
doi:10.1371/journal.pone.0034086.g004
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top 50% of the activity in the tumour. On one mouse, the
representation of data as %ID/cc showed a first phase of tumour
growth up to day 25 and then a sudden 5-fold increase in the
capability of the tumour to capture pertechnetate on day 32
(square on Fig. 7B). This sudden jump is inconsistent with the
visual comparison of the images at days 25 and 32 (Fig. 7A).
Normalisation of tumour to blood activities (square on Fig. 7C)
produced a dataset consistent with the volume-rendering images
presented in Fig. 7A. A very similar smoothing effect of the blood
normalisation was observed on a second animal (presented as
circles in Fig. 7B and C). The non-normalised data indicate a
stagnation in tumour growth between days 37 and 46 after
tumour-cells inoculation, while normalisation to blood activity
shows a constant increase in tumour size, more consistent with the
growth, in vivo, of HT29 tumour cells.The smoothing effect of
normalisation was observed on a total of 5 different mice (not
shown).
Discussion
In the present study, we highlight a problem which is likely to be
encountered when data obtained from gene expression imaging
analysis using the NIS reporter system are presented simply as a
percentage of the injected dose, or even as %ID/cc. Variation in
pertechnetate uptake levels by NIS expressing cells (either upon
administration of a gene-delivery vector or after ex-vivo genetic
engineering) can lead to inconsistencies with the subjective, visual
observation of the images, and false interpretations. The impact of
this problem can be reduced, or even removed, when data
obtained on a cohort of animals are pooled and analysed
statistically (see dataset and comments of Figure 5). However,
when the imaging dataset obtained from individual animals are
observed separately (in long-term kinetics, for example), the
‘statistical smoothing’ does not occur and great variability, and
even experimental inconsistencies, may be reported inadvertently.
These ‘noisy data’ may be attributed to the chaotic nature of the
phenomenon observed, while they are in fact largely due to a
methodological bias.
This problem is due to the fact that, upon administration of the
radiotracer, and despite following rigorously a standard operating
procedure, the concentration of the radiotracer in the blood varies
greatly from one individual to another and even within the same
individual when imaging is performed serially over a period of a
few days/weeks. Our analysis on more than twenty different
experimental points shows that a three-fold variation in the blood
activity can be found (Fig. 3A). Attempts to reduce this variability
by increasing or decreasing the length of time between radiotracer
administration and the beginning of the scan did not provide any
improvement (data not shown). On the contrary, our dataset tends
to suggest that reducing the time between radiotracer injection
and beginning the scan leads to an increased variability (data not
shown). The measurement of muscle activity is an option that may
be envisaged as an alternative (and sometimes more accessible
measure than blood activity) to normalise data. However, if neck
muscle activity appears to be well-correlated to blood activity
(R
2=0.90), quadriceps activity is not (R
2=0.30). These observa-
tions suggest that only of subset of muscles are suitable for
normalisation and that blood normalisation is the most reliable
way to normalise datasets. In addition, our data suggest that
normalisation of an ectopic expression of the NIS gene in the leg
muscle should be performed using the activity in the non-
transduced muscle.
The problem of radiotracer availability in the field of gene
expression imaging has already been highlighted by others using,
for example, a mutant Herpes simplex virus-1 thymidine kinase as a
reporter gene [35], but it is further emphasised by the specificity of
NIS-imaging: the radiotracer is not trapped inside the NIS-
expressing cells, its intra-cellular concentration being directly
dependent on its extracellular concentration. As a result, any
variation in the tracer plasma/blood concentration is likely to have
a dramatic effect on the quantitative data. This variability has also
been highlighted in humans in another context in which NIS-
mediated uptake of radio-iodide is a key factor: the radioiodine
ablation of remnant thyroid tissue [31,32,36]. Hanscheid et al.
[31] compared the thyroid remnant uptake after thyroid hormone
withdrawal and after administration of recombinant human TSH.
The difference in uptake between the two conditions disappeared
Figure 5. SPECT-imaging and quantitative RT-PCR analysis. (A)
Quantitative RT-PCR analysis of NIS expression in the liver of
adenovirus-injected mice. Total RNA was extracted from livers of mice
intravenously injected with either 5610
8 (circles) or 1610
9 (squares)
PFU Ad-CMV-rNIS, treated with DNase and reverse transcribed. Primers
for murine GAPDH RNAs were used for normalisation and the lowest
value was set as 1 arbitrary unit. DCt values were calculated by
subtracting the Ct of the GAPDH housekeeping gene from the Ct of the
targeted gene, measured in the same RNA preparation, and the lowest
value was set as 1 arbitrary unit. (B) Comparison of the activity of
adenovirus-transfected liver with the relative level of NIS mRNA. Balb/c
mice were injected intravenously with either 5610
8 (circles) or
1610
9 PFU (squares) Ad-CMV-rNIS. Four days later, 100 MBq
99mTcO4
2
were injected intraperitoneally and images were acquired on a SPECT/
CT camera. ROIs were drawn in left and right liver lobes and the average
activity was normalised to blood activity.
doi:10.1371/journal.pone.0034086.g005
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the blood in individual patients. This phenomenon is mainly
related to the different rate of renal clearance in the two situa-
tions. For a given transfer coefficient, the target tissue uptake
depends almost linearly on the blood activity, which is inversely
proportional to the rate of renal clearance. Similarly, Verbug
et al. [32] showed that absorbed dose in the blood is a better
predictor of ablation success than administered activity. This is
explained by the impact of renal clearance. If the clearance is
lower, the target tissue will have a considerably higher amount of
circulating iodide at its disposal, resulting in an increased efficiency
of the treatment. In this latter, retrospective study involving 449
Figure 6. Monitoring of NIS gene transfer in the liver after systemic Ad-CMV-rNIS administration. Balb/c mice were injected
intravenously with either 5610
8 (A, E, B, F) (n=2) or 1610
9 PFU (n=2) (C, D, G, H) Ad-CMV-rNIS. At different time-points after adenoviral
administration, 100 MBq
99mTcO4
2 were injected intraperitoneally and SPECT/CT imaging was performed. ROIs were drawn in left and right liver
lobes. The average activity was calculated and converted to percent of the injected dose per centimetre cubed (%ID/cc) (column 1, A–D). These
values were normalised with the blood (column 2, E–H) activities. In each graph, the data obtained on individual animals were plotted.
doi:10.1371/journal.pone.0034086.g006
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131I required to reach the critical
blood dose of 350 mGy varied from 1 GBq to 7 GBq, with the vast
majority of patients reaching this blood dose with an injected dose
varying from 2 GBq to 5 GBq [32]. This dataset demonstrates that
the variability in blood iodide or pertechnetate concentration is a
phenomenon shared by mice and humans and that the mode of
administration (intraperitoneal in our study in mice versus oral in
humans) has no effect on this variability. In mice, the anaesthesia is
probably amplifying this variability by affecting differentially the
hemodynamic parameters of the experimental animals [37,38].
To overcome the quantificationproblems caused by the variation
in blood radiotracer concentration, we propose to normalise the
data. The ratio of the accumulation of radiotracer in the transduced
organ to that in a non-transduced organ, taken as background, has
been proposed and used [29] without any formal validation.
Alternatively, the thyroid gland could be chosen as a reference. In
the course of the present study, we assessed whether thyroid activity
could be used as an alternative reference to blood activity. For each
experimental animal, regions of interest of 1 mm diameter were
drawn around the left and right thyroid glands and the average
activity of the whole gland was calculated. The activity in the liver
was then divided by that of the thyroid gland and our data show
that, as for ‘blood activity correction’, normalisation of liver activity
by thyroid activity provides a much more coherent dataset (not
shown). However, considering the difference in organification of
pertechnetate and iodide by the thyroid [39], this organ may not be
a ‘universal standard’ in NIS-imaging normalisation. By contrast,
and considering that NIS-mediated uptake and concentration of
iodide or pertechnetate is crucially dependent on the extracellular
concentration of these anions, we advocate that, when possible, the
blood activity should be determined and used to normalise the
activity measured in the organ/region of interest that expresses NIS
ectopically. Considering that NIS-imaging has now reached the
clinical setting in the context of cancer gene therapy [24,25] and
that recent pre-clinical studies have demonstrated the potential of
the methodology in the field of cell therapy, this normalisation may
be essential in order to obtain accurate and predictive information
in future clinical studies in biotherapy.
Materials and Methods
Adenovirus and NIS-expressing cell line
The replication-incompetent adenovirus, Ad-CMV-rNIS, in
which the immediate-early promoter of CMV drives the
expression of rat NIS, has been described previously [40]. This
virus was produced and titrated at the ‘‘Plateforme de production
de vecteurs pre ´-cliniques du CHU de Nantes’’, using a standard
protocol. The HT-29 cell line (HTB-38, ATCC) was transfected
with pcDNA3.1-mNIS (murine NIS) using the FuGENE 6 reagent
(Roche) according to the manufacturer’s instructions. Stable clones
were selected by adding 1 mg/ml geneticin (G418) to the medium
3 d after transfection. Demonstration of NIS expression in stably
transfected clones was performed by
125I uptake, western blot
analysis and immunostaining experiments, showing a strong
localisation of the NIS protein at the plasma membrane. One
clone (HT29-NIS) was selected for in-vivo imaging experiments.
Figure 7. Non-invasive monitoring of colorectal cancer liver metastases. (A) Volume-rendering images of a mouse bearing liver HT29-NIS
tumours (white arrow). The kinetics of tumour growth were monitored by SPECT imaging at days 11, 18, 25, 32 and 39 after injection of 2610
6 HT29-
NIS cells in the liver. Tracer also accumulated in the stomach (S). (B–C) Time course of
99mTcO4
2 accumulation in liver metastases as determined by
serial scanning. From each SPECT/CT image acquired in (A), a three-dimensional ROI was drawn around the liver tumour using a threshold of 50% of
the maximal activity. The counts in the ROI were calculated and expressed as (B) a percentage of the injected dose (%ID) accumulated in liver tumour
nodules or (C) normalised to the blood activity. Data of two individual animals are presented.
doi:10.1371/journal.pone.0034086.g007
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Animal housing and procedures were conducted according to the
guidelines of the FrenchAgriculture Ministry and were approved by
thelocalethicscommittee.Gene-transfer studies wereperformed on
female Balb/c mice obtained at 8 weeks of age from Janvier (Le
Genest Saint Isle, France). Ad-CMV-rNIS (5610
8 or 1610
9 PFU/
mouse) in sterile saline buffer (final volume, 200 ml) was adminis-
tered intravenously. Control animals were injected with 200 ml
saline buffer. For the induction of hepatic tumours, 2610
6 HT29-
NIS were injected under the liver capsule of anaesthetised, 7-week-
old SCID mice (Harlan, Gannat, France).
MicroSPECT/CT studies
Although thyroxin is used in some studies to reduce or block the
uptake of iodide or perctechnetate by the thyroid, all the
experiments in this study were performed on animals not treated
with thyroxin. At various times after adenovirus administration or
tumour-cell injection, mice were injected intraperitoneally with
100 MBq
99mTc pertechnetate (
99mTcO4
2) obtained from a
freshly eluted
99Mo/
99mTc generator. Precisely 20 min later, mice
were imaged under Isofluran anaesthesia (Baxter, Aerane).
SPECT/CT scans were performed using a micro-SPECT-CT
(eXplore speCZT CT120, General Electric), using a previously
published protocol [9,23].
Image analyses and quantitative determinations were performed
using the ‘AMIDE’ software [41]. For quantification, three-
dimensional regions of interest (ROIs) were outlined on each left
and right liver lobe/thyroid glands (4 mm and 1 mm diameter,
respectively). For blood content determination, a 2 mm diameter
ROI was drawn in the left ventricular cavity of the heart. This
method was used to calculate blood activity in all the mice of the
study. The voxel content was calculated and converted to percent
injected dose per cubic centimetre (%ID/cc). Values were then
corrected for decay of the radioisotope, taking 6 h as the half-life
of
99mTcO4
2.
b-counting of liver biopsies
Livers were recovered after cull and weighed. Radioactivity in
the organs was measured using a Medi404-calibrated dose
calibrator (Medisystem). Values were expressed as percentage of
the injected dose per gram of tissues (%ID/g) after correcting for
activity decay to the time of image acquisition. All activity values
were expressed with reference to the beginning of SPECT imaging
20 min after pertechnetate injection.
TaqMan real-time PCR experiments
Total RNA from the livers of mice injected intravenously with
either 5610
8 or 1610
9 PFU Ad- CMV-rNIS was extracted using
Nucleospin RNAII (Machereyl-Nagel, France) and transcribed
into cDNA using the Superscript III enzyme (Invitrogen, France).
Real-time PCR was performed with the 7900HT Fast Real-Time
PCR System and carried out using TaqManH gene expression
assays (Applied Biosystem, France). Primer sets were designed by,
and purchased from, Applied Biosystems. The sequence of the
primers is not available but the primers can be purchased form
Applied Biosystem, using the following reference numbers: Rn
00583900-m1 for NIS and Mm-013518-11 for GAPDH. Cycle
parameters were 95uC for 20 s followed by 40 cycles of 95uC for
1 s and 60uC for 20 s. Relative mRNA expression levels were
determined using DCt values obtained by subtracting Ct control
(mouse GAPDH) from Ct target gene (rat NIS), measured in the
same RNA preparation.
Immunohistochemistry
After culling the animals, livers were dissected, paraffin
embedded and cut into 4-mm-thick sections. The paraffin was
then removed and the sections were rehydrated and subjected to
an antigen-retrieval treatment with a solution of citrate buffer,
pH 6, using an automate (PT Link, Dako). Immunostaining was
performed following a standard protocol (Dako EnVisionTM
FLEX using an automated immunostainer, Autostainer, Dako).
Endogenous peroxide was blocked using the EnVisionTM FLEX
Peroxidase-Blocking Reagent. After pre-treatment, slides were
incubated for 20 min at room temperature with a rabbit
polyclonal antibody against NIS (antibody 25, see [42]) at a
1:200 dilution. rNIS immunostaining was performed with a
secondary antibody anti-mouse and rabbit/HRP (Dako, DM822)
using a 3,39 –diaminobenzidine (DAB) co-substrate [42]. The
DAB-stained sections were counterstained with Harris haematox-
ylin (Sigma, Saint Quentin Fallavier, France). Image acquisition
was performed using a Nikon 80i microscope equipped with a DS-
5M-L1 digital camera.
Statistical analysis
Statistical analysis was performed using Prism (GraphPad
software). Dual comparisons were made using the student t-test
and comparisons between multiple conditions were analysed using
ANOVA. Statistical significance was set at P,0.05.
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